Functional studies demonstrated that InhibinA effects on ovarian cancer were mediated by the co-receptor endoglin and ACVRL1 (ALK1), a type I receptor shared by the Activin and BMP subfamilies. Here, ACVRL1 is linked to ovarian cancer.